PCN66 A Cost and Outcomes Analysis of Bevacizumab plus Folfiri Versus Cetuximab Plus Folfiri for the Treatment of First-Line Metastatic Colorrectal Cancer Patients from the Brazilian Private Payer Perspective
Nov 1, 2011, 00:00
10.1016/j.jval.2011.08.1167
https://www.valueinhealthjournal.com/article/S1098-3015(11)02729-X/fulltext
Title :
PCN66 A Cost and Outcomes Analysis of Bevacizumab plus Folfiri Versus Cetuximab Plus Folfiri for the Treatment of First-Line Metastatic Colorrectal Cancer Patients from the Brazilian Private Payer Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)02729-X&doi=10.1016/j.jval.2011.08.1167
First page :
A446
Section Title :
Cancer
Open access? :
No
Section Order :
1124